Department of Pharmaceutical Sciences, Mercer University, Atlanta, GA, United States.
Int J Pharm. 2012 Feb 28;423(2):289-96. doi: 10.1016/j.ijpharm.2011.11.041. Epub 2011 Dec 6.
The objective of this study was to test low frequency sonophoresis at 20 kHz for delivery of ketoprofen into and across the skin. Permeation studies were carried out in vitro on excised hairless rat skin over a period of 24h using Franz diffusion cells after which, skin samples were subjected to skin extraction to quantify the amount of drug present in skin. Parameters like ultrasound application time, duty cycle coupling medium and distance of ultrasound horn from skin were optimized. Transepidermal water loss (TEWL) was measured to indicate the extent of barrier disruption following sonophoresis. Confocal microscopy was used to visualize dye penetration through sonophoresis treated skin. Application of ultrasound significantly enhanced permeation of ketoprofen from 74.87 ± 5.27 μg/cm(2) for passive delivery to 491.37 ± 48.78 μg/cm(2) for sonophoresis. Drug levels in skin layers increased from 34.69 ± 7.25 μg following passive permeation to 212.62 ± 45.69 μg following sonophoresis. TEWL increased from 31.6 ± 0.02 (passive) to 69.5 ± 12.60 (sonophoresis) indicating disruption of barrier properties. Confocal microscopy images depicted enhanced dye penetration through sonophoresis treated skin confirming barrier disruption. Low frequency sonophoresis with optimized ultrasound parameters can be effectively used to actively enhance transdermal and topical delivery of ketoprofen.
本研究旨在测试 20 kHz 低频超声对酮洛芬经皮渗透的作用。在体外使用 Franz 扩散池,对无毛大鼠皮肤进行了 24 小时的渗透研究,然后对皮肤样本进行皮肤提取,以定量测定皮肤中存在的药物量。优化了超声应用时间、占空比耦合介质和超声探头与皮肤的距离等参数。测量经皮水分丢失(TEWL)以指示超声处理后屏障破坏的程度。使用共聚焦显微镜可视化染料经超声处理的皮肤的渗透。超声的应用显著增强了酮洛芬的渗透,从被动传递的 74.87 ± 5.27 μg/cm(2) 增加到超声处理的 491.37 ± 48.78 μg/cm(2)。皮肤各层中的药物水平从 34.69 ± 7.25 μg(被动渗透)增加到 212.62 ± 45.69 μg(超声处理)。TEWL 从 31.6 ± 0.02(被动)增加到 69.5 ± 12.60(超声处理),表明屏障性质的破坏。共聚焦显微镜图像显示,超声处理后的皮肤染料渗透增强,证实了屏障破坏。优化超声参数的低频超声可有效用于主动增强酮洛芬的经皮和局部递送。
Int J Pharm. 2011-12-6
Pak J Pharm Sci. 2009-4
Front Bioeng Biotechnol. 2024-6-11
Drug Deliv Transl Res. 2024-11
Adv Healthc Mater. 2024-3
Drug Deliv Transl Res. 2022-4